为肉瘤患者实施精密瘤学:CCCLMU分子瘤经验委员会
Luc M Berclaz1, Anton Burkhard-Meier1, Philipp Lange2
1Department of Medicine III, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Marchioninistr. 15, 81377, Munich, Germany.
Journal of cancer research and clinical oncology
|August 5, 2023
概括
在先进的骨和软组织肉瘤 (BS/STS) 中,综合基因组分析 (CGP) 在超过三分之一的患者中发现了可采取行动的变化. 基于分子的疗法显示出潜在的益处,突出了NGS.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 精准医学是一门精准的医学.
背景情况:
- 先进的骨和软组织肉瘤 (BS/STS) 呈现出不良结果和有限的治疗选择.
- 综合分子分析 (CMP) 越来越多地用于确定BS/STS中的治疗点.
- 精密瘤学项目旨在将分子发现纳入临床决策.
研究的目的:
- 评估在专为BS/STS患者的精密瘤学计划中常规分子分析的影响.
- 评估可操作的分子变化的频率及其在德国肉瘤中心的临床实用性.
主要方法:
- 对92名接受综合基因组分析 (CGP) 的BS/STS患者进行了回顾性分析.
- 在2016年至2022年期间,瘤样本在分子瘤委员会 (MTB) 中进行了讨论.
- 评估了下一代测序 (NGS) 发现的临床影响.
主要成果:
- 71名患者 (82.6%) 患有至少一种分子变异,TP53突变是最常见的 (23.3%).
- 在32名患者 (37.2%) 中发现了可采取行动的变化,导致治疗建议.
- 十名患者接受了个性化治疗,六名患者从基于分子的治疗中获得了临床益处 (PFSr>1.3).
结论:
- 在BS/STS管理中实施精密瘤学显示了NGS采用率的增加,但面临着挑战.
- 很大一部分BS/STS患者有临床可行的变化.
- 对于BS/STS等罕见癌症,NGS提供了潜在的好处,治疗选择有限.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
557
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
557


